Effects of Lactobacillus plantarum on fat and hormones in obese women

Lactobacillus Plantarum Lp90 and Hormonal Regulation in Obese Women：A Randomized, Double-Blind, Placebo-Controlled Trial

This study tests if a daily probiotic called Lactobacillus plantarum can help reduce belly fat and balance hormones in obese women.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 100 (estimated)
• Ages: 18 Years to 40 Years
• Sex: Female
• Sponsor: Wecare Probiotics Co., Ltd. (Industry-sponsored)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Zhengzhou, Henan)
• Trial ID: NCT06987279 on ClinicalTrials.gov

What this trial studies

This study evaluates how the Lactobacillus plantarum Lp90 probiotic formula influences visceral fat metabolism and hormonal balance in obese women. Participants will be required to take the probiotic daily and provide blood, urine, and fecal samples for analysis. The study aims to understand the potential benefits of probiotics in managing obesity and related hormonal issues.

Who should consider this trial

Good fit: Ideal candidates are women aged 18 to 40 with a BMI of 25 or higher who are willing to participate in follow-up and provide biological samples.

Not a fit: Patients with gastrointestinal diseases or severe neurological disorders may not benefit from this study.

Why it matters

Potential benefit: If successful, this could provide a novel approach to managing obesity and improving hormonal balance in women.

How similar studies have performed: While the specific approach of using Lactobacillus plantarum for obesity management is relatively novel, other studies have shown probiotics can positively impact metabolic health.

Eligibility criteria

Inclusion Criteria:

1. Age: 18 to 40 years old, female, BMI ≥ 25 kg/m2.
2. Be willing to receive follow-up during the intervention period.
3. Be willing to provide two blood, urine and fecal samples during the intervention period.
4. Be willing to take the compound probiotics by oneself every day during the intervention period.
5. Have good hearing and be able to hear and understand all instructions during the intervention period.

   \-

Exclusion Criteria:

1. Suffering from digestive system diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease).
2. Suffering from severe neurological disorders (epilepsy, stroke, severe head trauma, meningitis within the past 10 years, brain surgery, brain tumor, long-term coma - excluding general anesthesia).
3. Have received/are currently receiving treatment for the following mental illnesses: alcohol/drug/substance abuse dependence, schizophrenia, psychosis, bipolar disorder.
4. Take medication for depression or low mood.
5. Suffering from internal organ failure (such as heart, liver or kidney failure, etc.).
6. Have received radiotherapy or chemotherapy in the past.
7. Have received general anesthesia surgery/procedures within the past three years, or plan to receive general anesthesia procedures/surgeries within the next three months during this trial.
8. Have suffered from hepatitis (hepatitis B, hepatitis C), HIV or syphilis in the past.

   \-

Where this trial is running

Zhengzhou, Henan

• Fuwai Central-China Cardiovascular Hospital — Zhengzhou, Henan, China (Recruiting)

Study contacts

• Study coordinator: Yingpeng Tian, Doctor

Conditions Obesity, Women